Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis
Authors:
Open Access
- 1 July 2015
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (7) , 1454-1465
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritisAnnals of the Rheumatic Diseases, 2011
- The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritisJournal of Autoimmunity, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001–2005Arthritis Care & Research, 2010
- Societal cost of rheumatoid arthritis patients in the USCurrent Medical Research and Opinion, 2009
- Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialThe Lancet, 2009
- Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care populationClinical Therapeutics, 2009
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group RegisterRheumatology, 2007
- Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyAnnals of the Rheumatic Diseases, 2007